FDA's Promotional Reviews Decline, But Says It's Only Part Of Job
US agency's Office of Prescription Drug Promotion may complete 37% fewer drug promotional material reviews in FY 2017 than previous year.
You may also be interested in...
Advertising Enforcement: US FDA Content To Let Competitors 'Duke It Out,' Woodcock Says
Office of Prescription Drug Promotion is focused on most egregious issues where human safety is at stake; CDER's Woodcock also says that First Amendment issues are affecting enforcement.
FDA Advertising Enforcement Highlighted By HHS Amid Drop In Citations
HHS blog post details activity of US FDA's Office of Prescription Drug Promotion during a year in which the office has only issued one enforcement letter, continuing a downward trend.
Off-Label Promotion Decisions Likely Made Case-by-Case, US FDA Official Says
OPDP chief Abrams did not give many general tips for complying with guidance on off-label promotion 'consistent with' FDA-approved labeling, leaving sponsors to make own interpretations.